Skip to main content

Table 2 Correlation of nuclear EZH2 expression with clinicopathological characteristics

From: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

   Nuclear EZH2 expression  
   0% 1-5% > 5-25% > 25-50% > 50%  
   n % n % n % n % n % p
Tumor extent (Robson)            0.0071
  Stage I 65 60 167 63 61 62 14 39 3 30  
  Stage II 9 8 24 9 2 2 2 6 0 0  
  Stage III 20 18 38 14 15 15 8 22 2 20  
  Stage IV 15 14 37 14 21 21 12 33 5 50  
Sex             0.984
  Male 67 61 161 61 63 64 23 64 6 60  
  Female 42 39 105 39 36 36 13 36 4 40  
Age at surgery            0.746
  < 65 years 58 53 148 56 61 62 22 61 6 60  
  ≥ 65 years 51 47 118 44 38 38 14 39 4 40  
Karnofsky performance status scale            0.404
  ≥ 80% 100 92 241 91 92 93 35 97 8 80  
  < 80% 9 8 25 9 7 7 1 3 2 20  
Tumor stage            0.019
  pT1/2 72 66 177 67 70 71 17 47 3 30  
  pT3/4 37 34 89 33 29 29 19 53 7 70  
Regional lymph node metastasis            0.003
  N0/pN0 103 95 250 94 93 94 28 78 7 70  
  pN+ 6 5 16 6 6 6 8 22 3 30  
Distant metastasis            0.005
  M0 94 86 231 87 78 79 24 67 6 60  
  M+ 15 14 35 13 21 21 12 33 4 40  
Fuhrman grade            < 0.0001
  G1/G2 91 83 224 85 78 80 20 56 4 40  
  G3/G4 18 17 39 15 19 20 16 44 6 60  
Histopathological subtype            < 0.001**
  Clear cell RCC 88 81 226 85 71 72 31 86 6 60  
  Papillary (chromophilic) RCC 7 6 27 10 17 17 3 8 1 10  
  Chromophobe RCC 11 10 8 3 4 4 0 0 0 0  
  Duct Bellini 0 0 0 0 0 0 2 6 1 10  
  Unclassified RCC 3 3 5 2 7 7 0 0 2 20  
Motzer criteria (metastatic RCC, n = 51)            0.731*
  Favorable 1 11 1 6 0 0 2 20 0 0  
  Intermediate 6 67 11 61 6 55 5 50 3 100  
  Poor 2 22 6 33 5 45 3 30 0 0  
  1. Fisher's exact test* using Monte Carlo Simulation**